StockData
Ovid Therapeutics Inc. logo

Ovid Therapeutics Inc. (OVID) stock

OVIDNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 10, 2026Score 10/30
$2.22−0.18 (-7.50%)

Close on Nov 17, 2026Market cap $433.56MP/E –Yield –

Ovid Therapeutics operating margin

Operating margin is operating income as a percentage of revenue.

Ovid Therapeutics's operating margin for the twelve months ending Jun 30, 2026 was -3686.7%. For fiscal 2025 it was -585.2%, against -10933.7% the year before. The highest annual figure on record is 59.6% in fiscal 2021.

Annual operating margin

PeriodPeriod endValueChange (pts)
FY2025Dec 31, 2025-585.2%+10348.5
FY2024Dec 31, 2024-10933.7%+4189.0
FY2023Dec 31, 2023-15122.7%−11426.3
FY2022Dec 31, 2022-3696.4%−3756.0
FY2021Dec 31, 202159.6%+705.0
FY2020Dec 31, 2020-645.4%–

Quarterly operating margin

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange (pts)
Q2 FY2026Jun 30, 2026-2141.6%+7512.2
Q4 FY2025Dec 31, 2025-1712.1%+12395.8
Q3 FY2025Sep 30, 2025-9487.1%−1842.0
Q2 FY2025Jun 30, 2025-80.9%+12059.4
Q1 FY2025Mar 31, 2025-9653.8%+2114.4
Q4 FY2024Dec 31, 2024-14107.9%−1299.4
Q3 FY2024Sep 30, 2024-7645.1%+3390.7
Q2 FY2024Jun 30, 2024-12140.2%+6755.8
Q1 FY2024Mar 31, 2024-11768.2%+10795.4
Q4 FY2023Dec 31, 2023-12808.5%+13494.3
Q3 FY2023Sep 30, 2023-11035.8%+104293.5
Q2 FY2023Jun 30, 2023-18896.0%−17770.5
Q1 FY2023Mar 31, 2023-22563.6%−22648.4
Q4 FY2022Dec 31, 2022-26302.7%−25924.2
Q3 FY2022Sep 30, 2022-115329.3%−115092.0
Q1 FY2022Mar 31, 2022-1125.5%–
Q1 FY2021Mar 31, 202184.7%–
Q4 FY2020Dec 31, 2020-378.6%–
Q3 FY2020Sep 30, 2020-237.3%–

More Ovid Therapeutics figures

See a number that looks wrong?